Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Share-based Compensation (2018 - 2025)

UroGen Pharma's Share-based Compensation history spans 8 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 5.24% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $12.0 million, down 8.77%, while the annual FY2025 figure was $12.0 million, 8.77% down from the prior year.
  • Share-based Compensation reached $3.1 million in Q4 2025 per URGN's latest filing, up from $3.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $6.2 million in Q1 2021 to a low of $2.2 million in Q2 2023.
  • Average Share-based Compensation over 5 years is $3.4 million, with a median of $3.0 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: crashed 55.8% in 2022, then soared 60.22% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $5.4 million in 2021, then crashed by 55.8% to $2.4 million in 2022, then grew by 10.3% to $2.6 million in 2023, then increased by 26.45% to $3.3 million in 2024, then decreased by 5.24% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Share-based Compensation are $3.1 million (Q4 2025), $3.0 million (Q3 2025), and $2.7 million (Q2 2025).